相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。In Situ immunization by bispecific antibody targeted T cell therapy in breast cancer
Archana Thakur et al.
ONCOIMMUNOLOGY (2016)
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
Achim Rothe et al.
BLOOD (2015)
A phase I/IIa study of IMCgp100: Partial and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma
Mark R. Middleton et al.
CANCER RESEARCH (2015)
The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy
Emese Zsiros et al.
CLINICAL CANCER RESEARCH (2015)
Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial
Lawrence G. Lum et al.
CLINICAL CANCER RESEARCH (2015)
Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street
David M. Barrett et al.
JOURNAL OF IMMUNOLOGY (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
ImmTACs for targeted cancer therapy: Why, what, how, and which
Joanne Oates et al.
MOLECULAR IMMUNOLOGY (2015)
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
Aaron P. Rapoport et al.
NATURE MEDICINE (2015)
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L. Garfall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies
Liping L. Sun et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates
Gurunadh R. Chichili et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Adoptive cellular therapy: A race to the finish line
Carl H. June et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Serial Killers and Mass Murderers: Engineered T Cells Are up to the Task
Carl H. June
CANCER IMMUNOLOGY RESEARCH (2015)
Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: A pilot study
L. G. Lum et al.
BONE MARROW TRANSPLANTATION (2014)
Engineered proteins with desired specificity: DARPins, other alternative scaffolds and bispecific IgGs
Christian Jost et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2014)
Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2-Bispecific Antibody Is Enhanced in Combination with Interferon-α
Edmund A. Rossi et al.
MOLECULAR CANCER THERAPEUTICS (2014)
A new class of bispecific antibodies to redirect T cells for cancer immunotherapy
Diane L. Rossi et al.
MABS (2014)
A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells
Uwe Reusch et al.
MABS (2014)
Bispecific antibodies rise again
Ken Garber
NATURE REVIEWS DRUG DISCOVERY (2014)
Characterization of a Novel Single-Chain Bispecific Antibody for Retargeting of T Cells to Tumor Cells via the TCR Co-Receptor CD8
Irene Michalk et al.
PLOS ONE (2014)
A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART®) protein in patients with relapsed/refractory metastatic colorectal carcinoma
Herbert Hurwitz et al.
Journal for ImmunoTherapy of Cancer (2014)
CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma
Lawrence G. Lum et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
An evolutionarily conserved program of B-cell development and activation in zebrafish
Dawne M. Page et al.
BLOOD (2013)
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
David T. Teachey et al.
BLOOD (2013)
Heterodimeric Bispecific Single-Chain Variable-Fragment Antibodies Against EpCAM and CD16 Induce Effective Antibody-Dependent Cellular Cytotoxicity Against Human Carcinoma Cells
Daniel A. Vallera et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2013)
Potent Immunomodulatory Effects of the Trifunctional Antibody Catumaxomab
Diane Goere et al.
CANCER RESEARCH (2013)
Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition
Andres Wiernik et al.
CLINICAL CANCER RESEARCH (2013)
Targeting T cells to tumor cells using bispecific antibodies
Stanley R. Frankel et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2013)
High Procedure Volume Is Strongly Associated With Improved Survival After Lung Cancer Surgery
Margreet Luechtenborg et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
Richard A. Morgan et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Potential of the Trifunctional Bispecific Antibody Surek Depends on Dendritic Cells: Rationale for a New Approach of Tumor Immunotherapy
Nina Eissler et al.
MOLECULAR MEDICINE (2013)
T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct
M. Aigner et al.
LEUKEMIA (2013)
Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients
Katrin S. Reiners et al.
MOLECULAR THERAPY (2013)
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications
Hannah Byrne et al.
TRENDS IN BIOTECHNOLOGY (2013)
TROP2 expression and its evolving role in tumor pathogenesis in systemic tumors
Shailendra Kapoor
TUMOR BIOLOGY (2013)
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
James N. Kochenderfer et al.
BLOOD (2012)
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Matthias Klinger et al.
BLOOD (2012)
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
Brian G. Till et al.
BLOOD (2012)
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
Max S. Topp et al.
BLOOD (2012)
T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 x CD3 or CD19 x CD16
Lisa M. Poertner et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Trifunctional Bispecific Antibodies Induce Tumor-Specific T Cells and Elicit a Vaccination Effect
Nina Eissler et al.
CANCER RESEARCH (2012)
RECRUIT-TandAbs®: harnessing the immune system to kill cancer cells
Fionnuala McAleese et al.
FUTURE ONCOLOGY (2012)
Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites
Marion G. Ott et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Generating Bispecific Human IgG1 and IgG2 Antibodies from Any Antibody Pair
Pavel Strop et al.
JOURNAL OF MOLECULAR BIOLOGY (2012)
Chronic renoprotective effect of pulsatile perfusion machine RM3 and IGL-1 solution in a preclinical kidney transplantation model
Raphael Thuillier et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
Matthias Friedrich et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production
Michelle K. Gleason et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Dual targeting strategies with bispecific antibodies
Roland E. Kontermann
MABS (2012)
Blinatumomab: A historical perspective
Dirk Nagorsen et al.
PHARMACOLOGY & THERAPEUTICS (2012)
Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells
Shu-Ru Kuo et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2012)
Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
Paul A. Moore et al.
BLOOD (2011)
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
Chrystal U. Louis et al.
BLOOD (2011)
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Renier J. Brentjens et al.
BLOOD (2011)
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
Oliver Kepp et al.
CANCER AND METASTASIS REVIEWS (2011)
Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
Dirk Nagorsen et al.
EXPERIMENTAL CELL RESEARCH (2011)
Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity
Kory L. Alderson et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
Barbara Savoldo et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
Maria R. Parkhurst et al.
MOLECULAR THERAPY (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function
Thomas Condamine et al.
TRENDS IN IMMUNOLOGY (2011)
The parallel lives of angiogenesis and immunosuppression: cancer and other tales
Gregory T. Motz et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CDI9-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
Michael C. Jensen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer et al.
BLOOD (2010)
Myeloid-Derived Suppressor Cells in Human Cancer
Srinivas Nagaraj et al.
CANCER JOURNAL (2010)
Immunity, Inflammation, and Cancer
Sergei I. Grivennikov et al.
CELL (2010)
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial
Markus M. Heiss et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16
Heiko Singer et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion
Syd Johnson et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
Improved Endpoints for Cancer Immunotherapy Trials
Axel Hoos et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Induction of Lymphoidlike Stroma and Immune Escape by Tumors That Express the Chemokine CCL21
Jacqueline D. Shields et al.
SCIENCE (2010)
Therapeutic antibodies for autoimmunity and inflammation
Andrew C. Chan et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Patrick A. Baeuerle et al.
CANCER RESEARCH (2009)
TROP2 expression as prognostic marker for gastric carcinoma
G. Muehlmann et al.
JOURNAL OF CLINICAL PATHOLOGY (2009)
Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab
Dirk Nagorsen et al.
LEUKEMIA & LYMPHOMA (2009)
Bispecific antibodies for cancer therapy The light at the end of the tunnel?
Patrick Chames et al.
MABS (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Brian G. Till et al.
BLOOD (2008)
High expression of TROP2 correlates with poor prognosis in pancreatic cancer
D. Fong et al.
BRITISH JOURNAL OF CANCER (2008)
Bi20 (FBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels
Michael Stanglmaier et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Sequential affinity purification of peroxidase tagged bispecific anti-SARS-CoV antibodies on phenylboronic acid agarose
Pravin K. Bhatnagar et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2008)
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity
Douglas C. Palmer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
The dock and lock method: A novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity
Chien-Hsing Chang et al.
CLINICAL CANCER RESEARCH (2007)
Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma
Julie R. Park et al.
MOLECULAR THERAPY (2007)
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting
EA Rossi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells
S Offner et al.
MOLECULAR IMMUNOLOGY (2006)
Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody
RM Sharkey et al.
NATURE MEDICINE (2005)
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct
P Hoffmann et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Two new trifunctional antibodies for the therapy of human malignant melanoma
P Ruf et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
High interstitial fluid pressure -: An obstacle in cancer therapy
CH Heldin et al.
NATURE REVIEWS CANCER (2004)
A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing
L Grosse-Hovest et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
ME Dudley et al.
SCIENCE (2002)
Designing heterodimeric two-stranded α-helical coiled-coils -: Effects of hydrophobicity and α-helical propensity on protein folding, stability, and specificity
JR Litowski et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Discovery of novel tumor markers of pancreatic cancer using global gene expression technology
CA Iacobuzio-Donahue et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
P Ruf et al.
BLOOD (2001)
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma
ME Dudley et al.
JOURNAL OF IMMUNOTHERAPY (2001)
Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors
M Sen et al.
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH (2001)
分享论文
